"Aimee Donnellan, Reuters columnist and author of Off the Scales: The Inside Story of Ozempic and the Race to Cure Obesity, joins me on this week's episode of The Real Health podcast to discuss how weight-loss drugs moved from medical niche to global phenomenon."
"Donnellan began writing the book before Ozempic became a household name, at a time when the obesity drug market was still flying under the radar."
"I started the book in 2023 and at the time. It wasn't the phenomenon it is today. It was really only kind of getting going. But Oprah Winfrey hadn't come out yet, and she hadn't been saying that she was on it. Elon Musk hadn't admitted to being on it. But there were signs, very early signs that it was really going to reshape business, which is what I cover at Reuters and also society, the food industry, all of those types of things."
Weight-loss drugs such as Ozempic moved from a medical niche into a widespread global phenomenon. The market began shifting around 2023, with early indicators showing potential to reshape business, societal attitudes, and the food industry. Celebrity disclosures and public figures later amplified awareness and accelerated adoption. Industry dynamics, media attention, and consumer demand combined to expand the obesity drug market beyond clinical settings. The trend has implications for healthcare, commerce, food production, and cultural perceptions of weight loss, and further coverage and firsthand commentary are available via a related podcast episode.
Read at Irish Independent
Unable to calculate read time
Collection
[
|
...
]